Reduced expression of serum miR-204 predicts poor prognosis of gastric cancer

Chen, X; Liu, X S; Liu, H Y; Lu, Yun; Li, Y

doi:10.4238/gmr.15027702

Cited by 19 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, microRNA-138 was identified as a critical tumor suppressor in different human cancers such as malignant melanoma and osteosarcoma ( 33 – 35 ). Moreover, miRNA-204 was downregulated in GC tissues and serum samples ( 25 , 36 ), and reduced miR-204 levels may be employed as a novel biomarker for monitoring the treatment response and predicting the prognosis of GC ( 37 ). Hence, we validated the biological relevance of these two miRs in GC tissues and GC cell lines.…”

Section: Discussionmentioning

confidence: 99%

Effects of miR‑138‑5p and miR‑204‑5p on the migration and proliferation of gastric cancer cells by targeting EGFR

Wang

Zhang

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

GC (gastric cancer) remains one of the most lethal malignancies worldwide. EGFR (epidermal growth factor receptor) plays an important role in the malignant process of GC, therefore, the present study addressed the relationship between EGFR and its potential regulators and examined their regulatory mechanisms in GC. We examined differences in the expression levels of EGFR in GC and adjacent non-cancerous tissues. Bioinformatics analyses and dual luciferase reporter assays were used to confirm the putative relationship between miR-138 or miR-204 and EGFR, and their relationship was further detected using western blotting, RT-PCR, and a series of cell studies. EGFR proteins were abundantly expressed in GC tissues, however EGFR mRNA levels remained indistinctive. Consequently, EGFR was revealed as a putative target of miR-138 and miR-204 which bound to the 3′UTR of EGFR mRNA. Further analysis revealed that miR-138 and miR-204 were significantly downregulated in GC tissues and the overexpression of miR-138 and miR-204 in GC cell lines resulted in the significant inhibition of EGFR protein levels and GC cell proliferation and metastasis. Rescue experiments confirmed that the roles of the two microRNAs were specific to EGFR. EGFR is a pivotal oncogene in GC progression that may be regulated by miR-138 and miR-204.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of miR‑138‑5p and miR‑204‑5p on the migration and proliferation of gastric cancer cells by targeting EGFR

Wang

Zhang

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…In a more recent study of Chen et al plasma expression of miR-204 was compared between 115 GC and 40 healthy individuals. Level of circulating miR-204 was significantly lower ( p < 0.01) in the cancer group and increased ( p < 0.01) after receiving the tumor resection (Chen et al, 2016). However, the study lacks of information what period after the operation the second plasma collection was performed.…”

Section: Methodsmentioning

confidence: 98%

Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response

2019

View full text Add to dashboard Cite

miRNAs can function as potential oncogenes or tumor suppressors. Altered expression of these molecules was correlated with the occurrence of many cancer diseases and therefore they are considered a molecular tool for non-invasive cancer diagnosis and prognosis. We searched for analyses concerning expression of blood circulating miRNA in cancer patients. The studies comprised of at least two miRNA expression measurements: before and after the surgical therapy were considered. We summarized latest reports on evaluation of the efficiency of anticancer therapy through observation of changes in expression of miRNA circulating in blood of patients treated with surgery alone. Twenty one research studies were identified. Thirty one different miRNAs were pointed out as potential both diagnostic and treatment response biomarkers since their deregulated expression before therapy returned to normal after receiving the treatment. Published data revealed a potential of circulating miRNA to become a tool giving a clinical follow up information on the efficiency of applied therapy. However, more observational studies on post-operative circulating miRNA expression changes are necessary.

show abstract

“… 80 Similarly, the serum miR-204 level was a biomarker for predicting prognosis in GC patients with systemic treatment. 91 A recent study showed that miR-21-5p was highly expressed in the urine of gastric cancer patients compared with healthy controls and noted that its expression was reduced following surgery, suggesting that urine miR-21-5p can be used as a valuable noninvasive biomarker to evaluate the prognosis of GC patients undergoing surgical treatment. 52 …”

Section: Mirnas As Therapeutic Biomarkers For Gastric Cancermentioning

confidence: 99%

MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer

Yuan

Wang

Zhang

2018

OTT

View full text Add to dashboard Cite

Despite the widespread use of endoscopy and conventional tumor biomarkers, gastric cancer (GC) remains one of the most frequent causes of cancer-related deaths worldwide due to its late diagnosis and poor response to treatment. Valuable and practical biomarkers are urgently needed to screen patients with a high risk of GC that can complement endoscopic diagnosis. Such biomarkers will enable the efficient prediction of therapeutic response and prognosis of GC patients and favor the establishment of an effective treatment strategy for each and every patient. MicroRNAs (miRNAs) are a class of small non-coding RNA sequences that play important roles in modulating key biological processes by regulating the expression of target genes. Expectedly, miRNAs are abnormally expressed within the tumor tissue and in associated biological fluids of GC patients including their blood, gastric juice, and urine. Accumulating evidence indicates that miRNAs are potential biomarkers with multiple diagnostic functions for GC. Here, we review recent advances and challenges in using miRNAs, particularly biofluid miRNAs, as GC biomarkers with potential clinical applications including diagnosing, clinically staging, and predicting malignant behaviors, therapy response, recurrence after surgery and survival time.

show abstract

Reduced expression of serum miR-204 predicts poor prognosis of gastric cancer

Cited by 19 publications

References 20 publications

Effects of miR‑138‑5p and miR‑204‑5p on the migration and proliferation of gastric cancer cells by targeting EGFR

Effects of miR‑138‑5p and miR‑204‑5p on the migration and proliferation of gastric cancer cells by targeting EGFR

Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response

MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer

Contact Info

Product

Resources

About